Search results
Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs
The Wall Street Journal· 13 hours agoEli Lilly has reached its first legal settlement with one of the spas that it had accused in...
Is Eli Lilly's Latest Deal a Gamechanger? | The Motley Fool
The Motley Fool· 22 hours agoOne of the biggest contributors to growth in the pharmaceutical industry right now is weight-loss...
Mounjaro vs. Ozempic: Which Is Better for Weight Loss?
MediaFeed via AOL· 2 days agoIn one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable...
Is Eli Lilly Stock A Buy Or A Sell As FDA Plans Meeting To Discuss Alzheimer's Drug?
Investor's Business Daily· 6 days agoLater in the year, Novo said a weekly shot of Ozempic helped stave off renal impairment and reduced...
Lilly's next-gen obesity drug brings Innovent a phase 3 win in diabetes
FierceBiotech· 6 days agoInnovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli ...
Innovent’s mazdutide superior to Trulicity in Phase III T2D trial
Clinical Trials Arena via Yahoo Finance· 5 days agoInnovent Biologics has said that its type 2 diabetes (T2D) candidate mazdutide was superior to Eli ...
Analyst Report: Lilly(Eli) & Co
Argus Research via Yahoo Finance· 22 hours agoEli Lilly, based in Indianapolis, develops and manufactures therapies to treat pain, diabetes, cancer, and neurodegenerative diseases. The shares are a component of the S&P 500.
2 Top Pharma Stocks That Just Keep Getting Better and Better
Motley Fool via Yahoo Finance· 19 hours agoEli Lilly Thanks to its smash-hit drugs for type 2 diabetes and obesity, Mounjaro and Zepbound, Eli ...
Is Eli Lilly Stock A Better Pick Over Amgen?
Forbes· 2 days agoAlso, Eli Lilly has seen a better revenue growth and is more profitable. There is more to the comparison, and in the sections below, we discuss why we...
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
Morningstar· 2 days agoWith strong pricing power and sales growth of key drugs, here’s what we think of Lilly’s stock. Eli ...